title: Is Modified Radical Hysterectomy Needed for Patients with Clinical Stage I/II Endometrial Cancers? A Historical Control Study.
abstract: OBJECTIVE
  The aim of the present study was to assess whether hysterectomy with wider resection could improve survival by preventing local recurrence.
  
  
  METHODS
  Medical charts of the patients with clinical stage I/II endometrial cancers treated at our hospital between 1990 and 2009 were retrospectively analyzed. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS) and adverse effects according to the type of hysterectomy.
  
  
  RESULTS
  A total of 247 patients were identified: 46 patients treated with total abdominal hysterectomy (TAH group) and 201 patients with modified radical hysterectomy (mRH group). No significant differences were observed in OS (p = 0.52) and PFS (p = 0.67) between the two groups. Also, there was no significant difference in the distribution of recurrent sites between the two groups. The patients treated with mRH had a longer operation time and more frequently developed severe adverse events, such as blood loss and lymphedema.
  
  
  CONCLUSIONS
  In our cohorts, there were no significant differences in both PFS and OS according to surgical procedures, and the mRH group more frequently developed severe adverse events. Overall, clinical benefit was not obtained by mRH in patients with clinical stage I/II endometrial carcinomas.
authors.affiliation: Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan.
authors.forename: Morikazu
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Masashi
authors.initials: M
authors.lastname: Takano
authors.forename: Tadashi
authors.initials: T
authors.lastname: Aoyama
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Soyama
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kato
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Shibutani
authors.forename: Hiroko
authors.initials: H
authors.lastname: Matsuura
authors.forename: Tomoko
authors.initials: T
authors.lastname: Goto
authors.forename: Hidenori
authors.initials: H
authors.lastname: Sasa
authors.forename: Isao
authors.initials: I
authors.lastname: Nagaoka
authors.forename: Kenichi
authors.initials: K
authors.lastname: Furuya
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D065386:Historically Controlled Study; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000379:methods*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate